Clinical Updates in Treating Advanced Prostate Cancer - Episode 11

Key Takeaways and Looking Ahead

October 28, 2024

Neal D. Shore, MD, Petros Grivas MD, PhD

Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.

EP. 1: Treatment Landscape and Sequencing of Therapies

EP. 2: Treatment Timelines Related to Disease State and Use of Monotherapy

EP. 3: Genetic Testing – Germline

EP. 4: Recent Data on ARPI-Based Combination Regimens

EP. 5: Genetic Testing – Somatic

EP. 6: ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

EP. 7: Use of Bone Protection Agents

EP. 8: ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

EP. 9: ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

EP. 10: ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

Now Viewing

EP. 11: Key Takeaways and Looking Ahead

ALL: Based on the new data and your clinical experience, what are the most important takeaways regarding the management of patients with metastatic prostate cancer?
ALL: What are the most pressing unmet needs or areas for future research in the treatment of advanced prostate cancer that clinicians should keep an eye on?
ALL: Do you have any additional advice or recommendations for how to optimize the care of patients with metastatic prostate cancer?